LMMY 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-06-16

• This Management’s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements include, without limitation, stateme…

• The Company was originally incorporated in the State of Wyoming on January 31, 2022, under the name LAMY. From its inception through November 17, 2025, the Company sought to develop a financial education platform for younger users featuring an immersive video game called TwoPlus1®. On November 17, 2…

• Exousia AI is a clinical-stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes, initially focused in the field of oncology. Substantially all of the Company’s prospective operations relate to the business of Exousia AI. We are a development-stage company wi…

• The following developments are material to a comparison of our historical financial condition and results of operations to expected future periods:

• • Change of Control and Acquisition. On November 17, 2025, in connection with the closing of the Reorganization Agreement, the Company’s prior sole officer and director resigned and Matthew Dwyer was appointed as the Company’s new Sole Officer and Director. The 62,223,000 Acquisition Shares were iss…

相对上期删除的文字 · 来源:10-Q · 2026-03-17

• We are a development-stage company with limited operations and no revenues from our business operations. Our independent auditor has issued a going-concern opinion. This means that our independent auditor believes there is substantial doubt that we can continue as an on-going business for the next t…

• Acquisition. On November 11, 2025, the Company entered into a Plan and Agreement of Reorganization (the “Reorganization Agreement”) with the shareholders of Exousia Ai, Inc., a Florida corporation (“Exousia AI”), pursuant to which the Company would acquire 100% of the issued and outstanding capital …

• The acquisition of Exousia AI was pursued and consummated by the Company, after the Company’s Board of Directors had determined, after investigating the Exousia AI opportunity, that the best interests of the Company and its shareholders would be best served by acquiring Exousia AI.

• Effective as of the closing of the Reorganization Agreement, Zhang Shengwu resigned as the Company’s Sole Officer and Director and Matthew Dwyer was appointed as the Company’s new Sole Officer and Director.

• New Plan of Business. The Company’s Board of Directors has adopted the business plan of Exousia AI as part of its overall business plan, to wit: Exousia AI is a clinical stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes, initially focused in the field o…